A Case of Dermatomyositis and Anti-EJ Autoantibody with Chronic Intestinal Pseudoobstruction Successfully Treated with Octreotide

Table 1

Characteristics of CIPO complicated with connective tissue disease treated with octreotide.

	Diagnosis	Sex/age	Octreotide (dosage, routes of administration)	Effect	Scleroderma	Raynaud’s phenomenon	Diminished esophageal peristalsis	ILD	Diarrhea	Constipation	Antibodies and other features
Soudah et al. 1991	SSc	M/63	50 μg, SC	+	+	+	n.a.	+	+	+	Myopathy
	SSc	F/65	50 μg, SC	+	+	−	n.a.	+	+	−
	SSc	F/60	50 μg, SC	+	+	+	n.a.	−	+	+
	SSc	M/57	50 μg, SC	+	+	−	n.a.	−	+	+
	SSc	M/55	50 μg, SC	+	+	+	n.a.	−	+	+
Kobayashi et al. 1993	SSc	F/26	50 μg, SC	+	+	+	n.a.	n.a.	+	−
Lanting et al. 1993	SSc/PM	F/51	50 μg, SC	+	+	n.a.	+	+	+	−
Yamamoto et al. 1994	SSc	F/29	100 μg, SC	+	+	n.a.	n.a.	+	+	+	α-RNP, myopathy
Ono et al. 1996	SSc	F/28	100 μg, SC	+	+	+	n.a.	+	−	+
	SSc	F/47	100 μg, SC	+	+	+	n.a.	+	−	−
Kanbe et al. 1996	SSc	F/61	100 μg, SC	+	+	+	n.a.	+	−	+
Ishikawa et al. 1999	SSc	F/66	SC	+	+	+	+	+	+	+
	SSc/PM	F/35	SC	+	+	+	+	−	−	+	α-RNP, Ku
Perlemuter et al. 1999	SS	F/19	100 μg, SC	+	−	−	n.a.	n.a.	−	+	α-RNP, SSA
	SLE	F/52	100–400 μg, SC	+	−	−	n.a.	n.a.	+	+	α-RNP, DNA
	SSc	F/70	50–100 μg, SC	+	+	+	+	n.a.	−	+	α-Scl-70, Jo-1, PM-1
Descamps et al. 1999	SSc/PM	F/53	75 μg, SC	+	+	+	n.a.	n.a.	−	+	Dysphagia
Matsuki et al. 2000	SSc	M/64	50 μg, SC	+	+	+	n.a.	+	−	+
	SSc	F/65	100 μg, SC	−	+	+	+	+	−	+	α-Scl-70
Marie et al. 2001	PM	M/55	50 μg, SC	+	−	−	−	−	−	+
Malcolm and Ellard 2001	SSc	F/75	50 μg, SC	−	+	+	−	+	+	−	Intestinal perforation
Suzuki et al. 2005	SSc/PM	F/31	100 μg, SC	−	+	+	+	−	−	+	α-Ku
Leonardi et al. 2010	SLE	F/51	50 μg, SC	−	−	n.a.	+	n.a.	−	+	PSL pulse was effective
Our case 2016	DM	F/38	100 μg IV, 50 μg SC, 30 mg IM	+	−	−	+	+	+	+	α-RNP, SSA, EJ

Dosage was not available, partial response.
ILD: interstitial lung disease; SSc: systemic sclerosis; SS: Sjögren’s syndrome; PM: polymyositis; DM: dermatomyositis; SLE: systemic lupus erythematosus; n.a.: not available.